Assenagon Asset Management S.A. Has $24.20 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Assenagon Asset Management S.A. boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 25.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,593 shares of the company’s stock after buying an additional 8,831 shares during the quarter. Assenagon Asset Management S.A.’s holdings in IDEXX Laboratories were worth $24,196,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Panagora Asset Management Inc. boosted its holdings in IDEXX Laboratories by 50.3% in the 1st quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock valued at $1,768,000 after purchasing an additional 1,081 shares during the period. Raymond James Trust N.A. boosted its holdings in IDEXX Laboratories by 26.8% in the 1st quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock valued at $888,000 after purchasing an additional 343 shares during the period. Cetera Investment Advisers boosted its holdings in IDEXX Laboratories by 77.1% in the 1st quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock valued at $2,010,000 after purchasing an additional 1,600 shares during the period. Moors & Cabot Inc. boosted its holdings in IDEXX Laboratories by 3.0% in the 1st quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock valued at $961,000 after purchasing an additional 52 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its holdings in IDEXX Laboratories by 15.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock valued at $543,000 after purchasing an additional 134 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 0.2 %

Shares of IDEXX Laboratories stock opened at $530.60 on Wednesday. The stock has a market capitalization of $44.09 billion, a P/E ratio of 52.69, a price-to-earnings-growth ratio of 2.90 and a beta of 1.27. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The company has a 50-day simple moving average of $547.55 and a 200 day simple moving average of $501.25. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last announced its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the company posted $2.05 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research reports. BNP Paribas initiated coverage on shares of IDEXX Laboratories in a report on Thursday, December 7th. They issued an “outperform” rating and a $602.00 price target for the company. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Friday, January 5th. Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a report on Tuesday, January 30th. Barclays raised their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $591.50.

View Our Latest Stock Analysis on IDXX

Insider Buying and Selling

In related news, SVP George Fennell sold 8,198 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock worth $24,871,960 in the last quarter. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.